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Background
Allergen-specific oral immunotherapy (OIT) aims to
induce desensitisation and immune tolerance, which
should if successful reduce the risk of further reactions
to peanuts and peanut-containing foods.
Methods
We performed a systematic review of intervention studies
by searching 13 databases and contacting an international
panel of experts. Studies were critically appraised using
Cochrane criteria.
Results
We identified one RCT with 28 children age 1-16 years
(19 in the OIT group and nine in the placebo group).
Because of allergic side-effects, three children were with-
drawn from the OIT group early in the study. The
remaining 16 participants in the OIT group completed
the study and ingested a maximum cumulative dose
(MCD) of 5000 mg (≈20 peanuts). All 9 participants in
the placebo group completed the study, but ingested an
MCD of only 280 mg (range, 0-1900 mg, P<0.001). Chil-
dren in the OIT group had reductions in peanut-specific
skin prick tests (P<0.001), IL-5 (P=0.01), and IL-13
(P=0.02), and increases in peanut-specific IgG4 (P<0.01)
and T reg cells. Nine children (47%) of the 19 in the
OIT group experienced side-effects and two of them
required epinephrine treatment.
Conclusions
We found one small RCT judged to be at low risk of bias
which showed that peanut OIT can result in desensitisation
in children, and that this is associated with evidence of con-
current immune-modulation. This treatment approach was
however associated with substantial risk of adverse reac-
tions, although most of these were mild. Thus, peanut OIT
cannot currently be recommended as a treatment for the
management of patients with IgE-mediated peanut allergy.
Larger RCTs are needed investigating the acceptability,
effectiveness and cost-effectiveness of safer treatment regi-
mens, particularly in relation to the induction of long-term
immune tolerance.
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